RapidAI vs VUNO
Both read the brain, so a neuroradiology unit can weigh them. For a stroke program that needs LVO and ICH alerts on CT, VUNO falls short. Its two openFDA decisions are DeepBrain (K231398, October 4, 2023) for MR and a chest X-ray triage tool (K241439), while RapidAI's Rapid ICH (K193087, March 31, 2020) and Rapid LVO (K200941, July 9, 2020) are triage and notification software.
RapidAI promotes the DUEL study (AJNR, May 2026): about 1,590 code strokes at a single center, retrospective, with 98% of confirmed LVOs detected against 73% for Viz.ai.
VUNO fits best in a neuroradiology service that reports white matter hyperintensity volume. DeepBrain labels and quantifies brain structures from 3D T1 images and adds white matter hyperintensity from 2D T2 FLAIR. A 2022 PLoS One study reported sensitivity of 96.4% and specificity of 89.9% for moderate to severe white matter hyperintensity volume.
Radiology · Reviewed November 2, 2026
When to pick each one
RapidAI
- Rapid ICH triage, K193087
- Rapid LVO triage, K200941
- Mobile app with case summaries
VUNO
- DeepBrain volumetry from MR, K231398
- White matter hyperintensity quantification
- ISO/IEC 27701:2019 certified
Score
Each row shows points earned of points available under the published rubric.
RapidAI
65of 100
VUNO
73of 100
| Dimension | RapidAI | VUNO | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 0 / 10 | 0 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 12.7 / 18.2 | 18.2 / 18.2 | -5.5 |
| RCT / meta-analysis / systematic review | 3.9 / 7.8 | 7.8 / 7.8 | -3.9 |
| Funding & adoption signal | 8.4 / 12 | 8.4 / 12 | 0 |
| Pricing transparency | 5 / 5 | 2.5 / 5 | +2.5 |
| Years in market | 6 / 6 | 6 / 6 | 0 |
Scroll horizontally to see every column.
Pricing
RapidAI
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Plan | n/a | n/a | Enterprise. |
VUNO
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Evidence
RapidAI
FDA decisions
K233512 (opens in new tab)510(k)2024-01-16
Rapid (6.0)
K213165 (opens in new tab)510(k)2022-02-08
Rapid
K200941 (opens in new tab)510(k)2020-07-09
Rapid LVO
K200760 (opens in new tab)510(k)2020-06-26
Rapid ASPECTS
K193087 (opens in new tab)510(k)2020-03-31
Rapid ICH
Show 2 more
K182130 (opens in new tab)510(k)2018-12-27
iSchemaView RAPID
K121447 (opens in new tab)510(k)2013-10-04
ISCHEMA VIEW RAPID
Peer-reviewed
4 PubMed records name RapidAI.
- A Comparison of CT Perfusion Output of RapidAI and Viz.ai Software in the Evaluation of Acute Ischemic Stroke. (opens in new tab)
- Transforming Stroke Diagnosis with Artificial Intelligence: A Scoping Review of Brainomix e-Stroke, Aidoc, RapidAI, and Viz.ai. (opens in new tab)
- Impact of RapidAI mobile application on treatment times in patients with large vessel occlusion. (opens in new tab)
VUNO
FDA decisions
K241439 (opens in new tab)510(k)2024-11-15
VUNO Med-Chest X-ray Triage / VUNO Med-CXR Link Triage
K231398 (opens in new tab)510(k)2023-10-04
VUNO Med-DeepBrain
Peer-reviewed
5 PubMed records name VUNO.
- A comparison of two artificial intelligence-based methods for assessing bone age in Turkish children: BoneXpert and VUNO Med-Bone Age. (opens in new tab)
- Clinical Effectiveness of AI-Based Cardiac Arrest Prediction System for General Ward Patients (VITAL-MD): Protocol for a Multicenter Pragmatic Stepped Wedge Cluster Randomized Controlled Trial. (opens in new tab)
- Combined diagnostic accuracy of two artificial intelligence systems for glaucoma diagnosis using color fundus photography. (opens in new tab)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | RapidAI | VUNO |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | 2017 | 2014 |
| HQ | US | KR |
Scroll horizontally to see both columns.
Common questions
Open the full radiology comparison
Acute-care triage, mammography screening, CCTA plaque analysis, mobile MRI. 30+ FDA-cleared platforms across stroke, oncology, cardiac. Enterprise sales only — we compared what's deployed where.